{"title":"Challenges and considerations in non-inferiority trials: a narrative review from statisticians' perspectives.","authors":"Ruizhe Chen, Qian Shi","doi":"10.21037/cco-24-84","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>Non-inferiority (NI) study is a popular randomized controlled trial design that aims to demonstrate whether a test treatment, considering its auxiliary benefits, is not unacceptably worse compared to a standard active control treatment. There is extensive work in the literature that discusses NI trials' merits, issues, and how certain clinical and statistical challenges can be addressed. Here, we are aimed to provide a narrative review of NI studies in terms of its design considerations, potential issues, and corresponding solutions from the perspectives of biostatisticians.</p><p><strong>Methods: </strong>We conducted a wide literature search on clinical and statistical methodology papers related to NI trials.</p><p><strong>Key content and findings: </strong>In the \"Fundamentals of NI study\" section, we start from the formulation of the margin and the NI hypothesis test and then focus on the underlying two fundamental assumptions (the constancy assumption and assay sensitivity). We present experts and regulatory agencies' opinions on how certain statistical issues of NI studies are caused and how they could be addressed. We focus on key aspects of NI studies, which include formulations of an NI hypothesis test, definition of NI margins, determining historical evidence of the active control drug, checking assay sensitivity and constancy assumption, etc. We also briefly touch on topics such as comparisons between the fixed-margin method and the synthesis method for NI evaluation, analysis principle in presence of treatment non-adherence, Bayesian design of NI studies, and restricted mean survival time (RMST) as a measure for designing NI studies. Figures and examples are given throughout the article to better illustrate ideas.</p><p><strong>Conclusions: </strong>We believe that NI design, with its issues addressed by appropriate statistical and clinical considerations, still plays a pivotal role in clinical research by improving patients' experience and alleviating healthcare inequalities.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"14 1","pages":"8"},"PeriodicalIF":2.1000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/cco-24-84","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and objective: Non-inferiority (NI) study is a popular randomized controlled trial design that aims to demonstrate whether a test treatment, considering its auxiliary benefits, is not unacceptably worse compared to a standard active control treatment. There is extensive work in the literature that discusses NI trials' merits, issues, and how certain clinical and statistical challenges can be addressed. Here, we are aimed to provide a narrative review of NI studies in terms of its design considerations, potential issues, and corresponding solutions from the perspectives of biostatisticians.
Methods: We conducted a wide literature search on clinical and statistical methodology papers related to NI trials.
Key content and findings: In the "Fundamentals of NI study" section, we start from the formulation of the margin and the NI hypothesis test and then focus on the underlying two fundamental assumptions (the constancy assumption and assay sensitivity). We present experts and regulatory agencies' opinions on how certain statistical issues of NI studies are caused and how they could be addressed. We focus on key aspects of NI studies, which include formulations of an NI hypothesis test, definition of NI margins, determining historical evidence of the active control drug, checking assay sensitivity and constancy assumption, etc. We also briefly touch on topics such as comparisons between the fixed-margin method and the synthesis method for NI evaluation, analysis principle in presence of treatment non-adherence, Bayesian design of NI studies, and restricted mean survival time (RMST) as a measure for designing NI studies. Figures and examples are given throughout the article to better illustrate ideas.
Conclusions: We believe that NI design, with its issues addressed by appropriate statistical and clinical considerations, still plays a pivotal role in clinical research by improving patients' experience and alleviating healthcare inequalities.
期刊介绍:
The Chinese Clinical Oncology (Print ISSN 2304-3865; Online ISSN 2304-3873; Chin Clin Oncol; CCO) publishes articles that describe new findings in the field of oncology, and provides current and practical information on diagnosis, prevention and clinical investigations of cancer. Specific areas of interest include, but are not limited to: multimodality therapy, biomarkers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to cancer. The aim of the Journal is to provide a forum for the dissemination of original research articles as well as review articles in all areas related to cancer. It is an international, peer-reviewed journal with a focus on cutting-edge findings in this rapidly changing field. To that end, Chin Clin Oncol is dedicated to translating the latest research developments into best multimodality practice. The journal features a distinguished editorial board, which brings together a team of highly experienced specialists in cancer treatment and research. The diverse experience of the board members allows our editorial panel to lend their expertise to a broad spectrum of cancer subjects.